What is HC Wainwright’s Forecast for TRVI FY2026 Earnings?

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Stock analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Trevi Therapeutics in a research report issued to clients and investors on Tuesday, November 10th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.49) per share for the year, down from their previous estimate of ($0.48). HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q4 2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at ($0.72) EPS.

A number of other research firms have also recently issued reports on TRVI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a report on Thursday, October 15th. Oppenheimer reissued an “outperform” rating on shares of Trevi Therapeutics in a report on Friday, September 25th. B. Riley Financial raised their price objective on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $40.00 target price on shares of Trevi Therapeutics in a research note on Friday, August 7th. Finally, Cantor Fitzgerald boosted their target price on shares of Trevi Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $27.08.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI opened at $14.81 on Thursday. Trevi Therapeutics has a twelve month low of $9.82 and a twelve month high of $20.22. The firm has a market cap of $2.11 billion, a PE ratio of -37.97 and a beta of 1.15. The business has a fifty day moving average of $14.17 and a 200-day moving average of $14.46.

Trevi Therapeutics (NASDAQ:TRVI) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13).

Hedge Funds Weigh In On Trevi Therapeutics

Several large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Trevi Therapeutics in the second quarter valued at about $208,041,000. Wellington Management Group LLP raised its holdings in Trevi Therapeutics by 9.5% during the 2nd quarter. Wellington Management Group LLP now owns 5,684,592 shares of the company’s stock worth $106,018,000 after purchasing an additional 495,504 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Trevi Therapeutics by 131.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,527,035 shares of the company’s stock valued at $50,507,000 after purchasing an additional 2,001,721 shares during the period. Artia Global Partners LP acquired a new position in Trevi Therapeutics during the 2nd quarter valued at about $41,232,000. Finally, First Light Asset Management LLC acquired a new position in Trevi Therapeutics during the 2nd quarter valued at about $39,113,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

Insider Activity at Trevi Therapeutics

In other news, Director Michael Heffernan sold 39,473 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total transaction of $595,647.57. Following the completion of the sale, the director owned 6,351 shares in the company, valued at $95,836.59. The trade was a 86.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 15.39% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis. Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.